Combination Therapy
OwnerAnita Chugh, Mohammad Salman +3inventors
InventorsAnita Chugh, Mohammad Salman, Atul Tiwari, Gowri R. Shankar, Sandeep Sinha
Life of this patent
Estimating the term…
Abstract
This invention relates to combination therapy for the treatment of lower urinary tract symptoms (LUTS) associated with or without benign prostatic hyperplasia (BPH). The combination therapy comprises of tailored 1 adrenoceptor antagonist, which is selective for 1a over 1b subtype but non-selective for 1a over 1d subtype, in combination with muscarinic receptor antagonist, preferably bladder selective antagonist and optionally included 5-reductase inhibitor for relief of LUTS in a mammal with or without BPH.
Claims52
A pharmaceutical composition comprising a tailored α1-adrenoceptor antagonist, a bladder-selective antagonist and optionally included 5α-reductase inhibitor, optionally together with pharmaceutically acceptable carriers, excipients or diluents.
A pharmaceutical product or medicament comprising a first pharmaceutical composition of a tailored α1 adrenoceptor antagonist, a second pharmaceutical composition of a bladder selective antagonist and optionally included a third pharmaceutical composition of 5α-reductase inhibitor.
method for treatment of a mammal suffering from lower urinary tract symptoms (LUTS) associated with or without BPH, comprising administering to said mammal, a therapeutically effective amount of a product or medicament, comprising a tailored α1 AR antagonist, a bladder-selective antagonist and optionally included 5α-reductase inhibitor.
Dependencies are inferred from the claim text.